大行評級|花旗:下調滔搏目標價至8.3港元 維持“買入”評級
花旗發表報吿指出,滔搏將於5月底披露截至今年2月底止2024財年業績,該行預期公司淨利潤按年增長21%至22.31億元,收入預測升8%,毛利擴張。
該行對滔搏2024財年淨利潤預測基本不變,惟預計行業增長放緩,對2025財年及2026財年預測各下調7%與11%。此外,該行指滔搏受惠於國際品牌持續增加市場份額,料公司2025財年及2026財年收入增長11%與10%,超過行業水平。
該行對其目標價由9.4港元下調至8.3港元,維持“買入”評級。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.